Sagimet Biosciences Inc (SGMT)
4.06
+0.14
(+3.57%)
USD |
NASDAQ |
Apr 26, 16:00
4.07
+0.01
(+0.25%)
After-Hours: 20:00
Sagimet Biosciences Cash from Operations (TTM): -23.77M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -23.77M |
| September 30, 2023 | -24.14M |
| June 30, 2023 | -26.49M |
| March 31, 2023 | -26.91M |
| Date | Value |
|---|---|
| December 31, 2022 | -24.49M |
| September 30, 2022 | -21.94M |
| June 30, 2022 | -18.30M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-26.91M
Minimum
Mar 2023
-18.30M
Maximum
Jun 2022
-23.72M
Average
-24.14M
Median
Sep 2023
Cash from Operations (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | -324.23M |
| 89bio Inc | -129.19M |
| Viking Therapeutics Inc | -54.87M |
| Akero Therapeutics Inc | -145.37M |
| Arrowhead Pharmaceuticals Inc | -196.21M |